** Shares of drug developer Metsera MTSR.O rise 17.28% to $32.24 premarket
** Co says its experimental weight loss drug, MET-233i, hit up to 8.4% weight loss, on placebo adjusted basis, at 36 days in a small, early-stage trial
** MET-233i, a long-acting injectable monthly amylin analogue, is being developed as a standalone treatment and in combination with another experimental GLP-1 drug MET-097i
** The trial studied MET-233i in 80 participants with overweight or obesity without type 2 diabetes
** Up to last close, stock up 3.7% since it went public in January
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。